Search clinical trials for: Open cell stent

Total 60539 results

Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IVA Oropharyngeal Carcinoma AJCC v7 | Stage IVB Oropharyngeal Carcinoma AJCC v7

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Nantes University Hospital

Active, not recruiting

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03)

Multiple Myeloma at First Relapse

France
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Johns Hopkins University
New York University

Completed

Retrospective Review of Xen Gel Stent Implantation With Open vs. Closed Conjunctiva Approach

Glaucoma, Open-Angle

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); American Cancer...

Completed

Cetuximab in Head and Neck Cancer Patients

Head and Neck Cancer | Squamous Cell Carcinoma

United States
Medical University of Vienna

Terminated

Effect of Packed Red Blood Cell Transfusion on Eicosanoid Profiles in Plasma of Intensive Care Patients (EICOTRANS-p)

Critical Illness | Anemia | Lung Transplantation | Open Aortic Surgery

Austria
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Assistance Publique - Hôpitaux de Paris

Completed

Cost-utility Analysis of Fenestrated Aortic Stents Versus Open Surgery for the Treatment of Complex Abdominal Aortic Aneurysms (ORFEVAR)

Complex Abdominal Aortic Aneurysm, ie. Juxtarenal or Suprarenal Aortic Aneurysms, Treated by Fenestrated Endovascular Aortic Aneurysm Repair or Open Repair

France
National Cancer Institute (NCI)

Terminated

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States
Sorrento Therapeutics, Inc.

Withdrawn

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Light Chain (AL) Amyloidosis
Phillip Freeman
Odense University Hospital; Aarhus University Hospital; Biosensors International and other collaborators

Active, not recruiting

Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent (SORTOUTXI)

Coronary Artery Disease

Denmark
Queensland Centre for Gynaecological Cancer
M.D. Anderson Cancer Center

Completed

Laparoscopic Approach to Cervical Cancer (LACC)

Cervical Cancer

United States, China, Korea, Republic of, Australia, Canada, Italy, Argentina, Brazil, Bulgaria, Colombia, Mexico, Peru, Puerto Rico
Kocaeli University

Active, not recruiting

Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study

Renal Cell Carcinoma

Turkey
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
Gwo Xi Stem Cell Applied Technology Co., Ltd.

Active, not recruiting

An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients With Chronic Stroke

Chronic Stroke

Taiwan
NovoCure GmbH

Active, not recruiting

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

United States, China, Israel, Spain, Austria, Canada, Hong Kong, Germany, France, Bulgaria, Croatia, Hungary, Italy, Poland, Serbia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
Young Jin Youn, MD, PhD
Genoss Co., Ltd.

Completed

Genoss DES Prospective Multicenter Registry

Myocardial Infarction | Myocardial Ischemia | Coronary Artery Disease

Korea, Republic of
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
JOTEC GmbH

Completed

Prospective/Retrospective Registry of the E-vita OPEN PLUS Stent Graft System in France (FEOR)

Vascular Diseases

France
Cordis Corporation

Completed

A Multicenter, Open Label, Prospective, Non-Randomized Study Of INCRAFT™ In Subjects With AAA (INNOVATION) (INNOVATION)

Abdominal Aortic Aneurysms

Germany
Poitiers University Hospital
Sanofi; Celgene; Amgen; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

France
Gradalis, Inc.

Completed

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Ewing's Sarcoma

United States
Glaukos Corporation

Terminated

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Primary Open-Angle Glaucoma

United States
AbbVie
Roche-Genentech

Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Chronic Lymphocytic Leukemia

United States
George Washington University
Janssen Scientific Affairs, LLC

Completed

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Lymphoma, T-Cell

Japan
Bristol-Myers Squibb
PPD

Completed

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (Checkmate 171)

Non-Small Cell Lung Cancer

Poland, Spain, Austria, Denmark, Finland, Greece, Hungary, Ireland, Portugal, Romania, Russian Federation, Sweden, United Kingdom
Amgen
Daiichi Sankyo, Inc.

Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Cancer | Multiple Myeloma | Bone Metastases | Hematologic Malignancies | Oncology | Multiple Myeloma Bone Lesions

United States, Germany, Italy, Spain, Canada, France, Czechia, Hungary, Korea, Republic of, Russian Federation, United Kingdom, Taiwan, Australia, Hong Kong, New Zealand, Austria, Slovakia, Portugal, Greece, Bulgaria, Poland, Ukraine and more
Amgen

Terminated

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia

United States
Janssen Research & Development, LLC

Completed

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Urinary Bladder Neoplasms

United States, Spain
University Hospital, Antwerp

Completed

Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis

Atherosclerosis | Restenosis

Belgium
AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Glaukos Corporation

Completed

Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication

Open Angle Glaucoma

Armenia
Glaukos Corporation

Completed

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Open-angle Glaucoma

Armenia
Glaukos Corporation

Completed

Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

Open-angle Glaucoma

Armenia
Glaukos Corporation

Completed

Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents

Open-Angle Glaucoma

Armenia
Poitiers University Hospital
Sanofi; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Multiple Myeloma | Myeloma

France
CarThera

Completed

Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 (SC9-GBM-01)

Glioblastoma, Adult

United States, France
Glaukos Corporation

Completed

A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent

Subject With Primary Open-angle Glaucoma (POAG)

Armenia
Glaukos Corporation

Completed

Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty

Open-angle Glaucoma

Armenia
Glaukos Corporation

Completed

Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery

Open-angle Glaucoma

Armenia
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Sunnybrook Health Sciences Centre

Completed

An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis (EBRT)

Carcinoma, Neuroendocrine

Canada

Search clinical trials for: Open cell stent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations